Boston Scientific's Operating Profit Climbs Unexpectedly

Boston Scientific posted a third-quarter net loss on Friday, hit by hefty acquisition and divestiture charges.

Boston Scientific Corp.
Chitose Suzuki
Boston Scientific Corp.

The company -- which earlier this week announced a restructuring that includes cutting its work force by 9 percent -- forecast fourth-quarter earnings of 14 cents to 19 cents a share, excluding charges related to acquisitions, divestitures and restructuring. It estimated fourth-quarter sales at $2.05 billion to $2.15 billion.

The consensus estimate on Wall Street is for fourth-quarter profit of 19 cents per share, excluding one-time items, according to Reuters Estimates.

For the third quarter, the medical device maker reported a net loss of $272 million, or 18 cents per share, compared with a year-earlier profit of $76 million, or 5 cents per share.

Excluding special items, the company posted a profit of 20 cents per share. On that basis, the consensus estimate on Wall Street was 16 cents per share, according to Reuters Estimates.

Third-quarter sales were $2.048 billion, up slightly from $2.026 billion a year earlier.

Sales of drug-eluting heart stent systems were $448 million in the quarter, down from $572 million a year ago.

Sales of devices that regulate heart rhythms rose to $517 million from $446 million. The total includes implantable cardioverter defibrillator, or ICD, sales of $372 million, up from $315 million.

Shares of Boston Scientific closed at $13.85 on Thursday on the New York Stock Exchange.

Contact Earnings


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More